Our findings support future clinical studies to investigate the clinical utility of this combination strategy for treating HER2+ breast cancer while evaluating PPP2R2B as a potential predictive marker of anti-HER2 therapy. The gene discussed is ERBB2; the disease is breast carcinoma.